A powder X-ray diffractometer, D2 Phaser with Lynxeye (Bruker, Germany) was used to assess the crystallinity of prednisolone in the drug loaded tablets. Samples were scanned from 2Theta = 5° to 50° using a scan type coupled with a two theta/theta scintillation counter over 30 min. A Mettler Toledo DSC823e DSC (Mettler, Switzerland) was utilized to perform thermal analysis. MS-275 concentration Samples of approximately 5 mg were accurately weighed and placed in a 40 μL standard aluminium pan DSC analysis. Analysis was carried on under a nitrogen

environment (50 mL/min). In order to exclude the effect of humidity, samples were heated to 100 °C for 5 min then cooled to −20 °C at a rate of 10 °C/min. This was followed by a heat scan from −20 °C to 300 °C at a rate of 10 °C/min. All measurements were carried out in triplicates. A flow-through

cell (Sotax, Switzerland) dissolution apparatus with an open loop system was utilized to assess drug release pattern from the 3D printed tablets. The dissolution apparatus was connected to piston pumps and a fraction collector (Sotax, Switzerland). Cells of 12 mm diameter containing selleck chemicals 5 mm glass beads were utilized during the study. Filtration was conducted using 25 mm glass microfiber filter discs (FG/B) (Whatman, US) which were placed above the cells. The prednisolone loaded tablets were analysed using dissolution media of a pH 1.2 (HCl 0.1 M) for 2 h followed by phosphate buffer (pH 6.8) for additional 22 h at 37 ± 0.5 °C. The flow rate was 8 ml/min and samples were collected to Sotax fraction collector at time intervals 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 15, 18, 21 and 24 h. Samples were further filtered through 0.22 μm Millex-GP syringe filter (Merck Millipore, USA) and analysed by HPLC (section 2.5). Three tablets of each strength were assessed. Ellipse shaped tablets were printed using an FDM 3D printer loaded with original PVA (drug free) filament. When a series of PVA tablet with increasing dimensions were printed, a high level of correlation was identified between the theoretical volume of the

tablet ADP ribosylation factor design and the mass of the printed tablets (R2 = 0.9996). This indicated the ability of FDM 3D printing method to achieve a sufficient control of the mass of the printed tablets. Such ability is a key advantage for developing a mini-manufacturing unit that can tailor tablet mass by manipulating the volume of the design through an input on software. In order to investigate the ability of the printed tablet to contain a given dose of API and control its release, a model drug needed to be incorporated into PVA filament before loading it in the nozzle of the 3D printer. Prednisolone was chosen as a model drug due to its high thermal stability and neutral nature. A simple loading process based on incubation in methanolic solution was developed. The yielded prednisolone loaded filament showed a drug loading of approximately 1.9% w/w.